Geode Capital Management LLC increased its position in Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) by 8.1% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 638,633 shares of the biotechnology company’s stock after buying an additional 47,907 shares during the period. Geode Capital Management LLC’s holdings in Progenics Pharmaceuticals were worth $6,028,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in PGNX. Vanguard Group Inc. raised its position in Progenics Pharmaceuticals by 46.1% in the first quarter. Vanguard Group Inc. now owns 4,132,770 shares of the biotechnology company’s stock worth $39,013,000 after buying an additional 1,304,487 shares during the last quarter. Thrivent Financial For Lutherans purchased a new position in shares of Progenics Pharmaceuticals during the first quarter worth approximately $374,000. Legal & General Group Plc raised its position in shares of Progenics Pharmaceuticals by 576.8% in the first quarter. Legal & General Group Plc now owns 116,476 shares of the biotechnology company’s stock worth $1,100,000 after buying an additional 99,267 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Progenics Pharmaceuticals by 7.6% in the first quarter. Teachers Advisors LLC now owns 120,479 shares of the biotechnology company’s stock worth $1,137,000 after buying an additional 8,544 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in shares of Progenics Pharmaceuticals by 142.9% in the first quarter. Wellington Management Group LLP now owns 221,081 shares of the biotechnology company’s stock worth $2,087,000 after buying an additional 130,046 shares in the last quarter. Institutional investors own 92.20% of the company’s stock.

Shares of Progenics Pharmaceuticals Inc. (NASDAQ PGNX) opened at 5.115 on Thursday. The company has a market capitalization of $359.20 million, a price-to-earnings ratio of 52.732 and a beta of 3.35. The company’s 50-day moving average price is $6.61 and its 200-day moving average price is $8.22. Progenics Pharmaceuticals Inc. has a one year low of $4.60 and a one year high of $11.72.

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.04. The firm had revenue of $2.77 million for the quarter, compared to the consensus estimate of $3.34 million. Progenics Pharmaceuticals had a net margin of 10.24% and a return on equity of 7.50%. Progenics Pharmaceuticals’s quarterly revenue was down 67.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.08) earnings per share. On average, equities research analysts predict that Progenics Pharmaceuticals Inc. will post ($0.86) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/geode-capital-management-llc-has-6-03-million-stake-in-progenics-pharmaceuticals-inc-pgnx/1470522.html.

A number of research analysts have commented on PGNX shares. Needham & Company LLC reaffirmed a “strong-buy” rating on shares of Progenics Pharmaceuticals in a report on Monday, April 24th. Zacks Investment Research upgraded Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. ValuEngine downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd. TheStreet downgraded Progenics Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Friday, May 26th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $12.00 target price on shares of Progenics Pharmaceuticals in a research report on Thursday, June 8th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Progenics Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $12.33.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals Inc. (NASDAQ:PGNX).

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.